PMEL and lymphangioleiomyomatosis: To investigate the histopathological changes in the lung after sirolimus therapy, we established measurement models to observe the LAM cyst area and interstitial septal thickness in the lung tissues of patients with LAM treated with or without sirolimus by immunohistochemically staining for HMB45, a LAM cell marker (Figure 3a).